This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study
by Zacks Equity Research
Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.
AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study
by Zacks Equity Research
AstraZeneca (AZN) announces positive overall survival results from the phase III CASPIAN study evaluating Imfinzi in first-line extensive-stage SCLC.
Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger
by Kinjel Shah
AbbVie (ABBV) announces definitive deal to buy Allergan (AGN). Bristol-Myers (BMY) set to sell Celgene's Otezla to complete the impending merger.
Dow 30 Stock Roundup: Nike Earnings Disappoint, Walgreens Boots Margins Drop
by Swarup Gupta
The index suffered a disappointing week, declining over three straight trading sessions
Lilly's Study on Higher Doses of Trulicity Meets Endpoint
by Zacks Equity Research
Lilly's (LLY) phase III study evaluating higher doses of Trulicity meets primary and secondary efficacy endpoints.
Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits
by Zacks Equity Research
Activist investor, Elliott Advisors, discloses a 1.1-billion-euro ($1.3 billion) stake in Bayer (BAYRY). It forms a new committee and hires U.S. lawyer Beisner to fight its glyphosate litigations.
Conatus' Emricasan Lags Primary Goal in Liver Function Study
by Zacks Equity Research
Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.
Pfizer (PFE) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $43.76, marking no change from the previous day.
Abbvie Decides to Acquire Allergan
by Zacks Equity Research
Abbvie Decides to Acquire Allergan
AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20
by Mark Vickery
AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.
Why These Innovative Biotech ETFs Are Soaring
by Neena Mishra
Strong M&A activity has sent shares of many small, innovative biotech companies surging
Eldorado to Buy Caesars
by Zacks Equity Research
Eldorado to Buy Caesars
BioMarin Gets $15M From Pfizer on Talzenna's European Nod
by Zacks Equity Research
BioMarin (BMRN) gains a $15-million milestone from Pfizer on the approval of its breast cancer drug in Europe.
U.S. Senate Takes on Big Tech, Plus "Merger Monday"
by Mark Vickery
Eldorado Resorts (ELR) has agreed to buy Caesars (CZR) for $8.6 billion, and a bipartisan bill in the Senate holds Big Tech accountable for monetized user data.
Pfizer's Talzenna Gets Approval in Europe for Breast Cancer
by Zacks Equity Research
Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.
Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma
by Swarup Gupta
The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.
Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
by Zacks Equity Research
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
by Kinjel Shah
Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
Stock Market News For Jun 20, 2019
by Zacks Equity Research
Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
by Zacks Equity Research
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.
Big Drugmakers That May Tread the M&A Path After Pfizer
by Kinjel Shah
There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $43.08 in the latest trading session, marking a +0.45% move from the prior day.
Protalix (PLX) Completes Enrollment in Fabry Disease Study
by Zacks Equity Research
Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.
Pfizer-Array Biopharma Deal Bump Up Biotech ETFs
by Sweta Killa
Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.
Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio
by Zacks Equity Research
Pfizer (PFE) offers $48 per share to buy Array BioPharma and strengthen its cancer portfolio.